<DOC>
	<DOCNO>NCT02121145</DOCNO>
	<brief_summary>In recent control study , investigator explore cross-reactive immune response different Salmonella spp . healthy volunteer immunize either oral ( Vivotif® ) parenteral ( Typherix® ) typhoid vaccine ( ISRCTN68125331 ) . In present study immune response study group receive vaccine previously immunize volunteer booster immunization ( group receive vaccine 2-4 year primary immunization ) .</brief_summary>
	<brief_title>Cross-reactive Immunity Elicited Oral Parenteral Typhoid Vaccines</brief_title>
	<detailed_description>Many Salmonella spp cause gastroenteritis share O antigen serotypes Salmonella enteritidis subsp . enterica serovar Typhi ( S.typhi ) could therefore 'reach ' protective efficacy oral live typhoid fever vaccine Vivotif® . Some Salmonellae common cause diarrhoea traveller ( 0-30 % traveller diarrhea depend area ) . In recent control study , investigator show cross-reactive immune response elicit different Salmonella spp . healthy volunteer immunize either oral ( Vivotif® ) parenteral ( Typherix® ) typhoid vaccine ( ISRCTN68125331 ) . In present study immune response study group receive vaccine previously immunize volunteer booster immunization ( group receive vaccine 2-4 year primary immunization ; group : Vivotif / Typherix / Vivotif + Typherix ) . The result compare obtained primary immunization .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Male female subject age ≥18 ≤65 year 2 . General good health establish medical history physical examination 3 . Written inform consent 4 . Females childbearing potential must agree use efficacious hormonal barrier method birth control study . Abstinence acceptable . 5 . Available visit schedule study . 1 . Primary group : Vaccination typhoid fever within 5 year dose . 2 . History clinical typhoid fever , clinical paratyphoid A B fever . 3 . Immunization vaccine ( oral parenteral ) within 4 week prior study start plan vaccination study 4 . Current intake antibiotic end antibiotic therapy &lt; 8 day first IMP administration 5 . Chronic ( longer 14 day ) administration immunosuppressant immunemodifying drug within 6 month first dose investigational vaccine ; oral corticosteroid dosage ≥0.5 mg/kg/d prednisolone equivalent exclude ; inhale topical steroid allow 6 . Acute chronic clinically significant gastrointestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Vivotif</keyword>
	<keyword>Typherix</keyword>
	<keyword>Salmonella Typhi</keyword>
	<keyword>non-typhoid Salmonella</keyword>
	<keyword>Salmonella Paratyphi</keyword>
	<keyword>enzyme-linked immunospot assay</keyword>
	<keyword>Plasmablast</keyword>
</DOC>